Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
YKL-06-061 is an inhibitor of salt-inducible kinase 1 (SIK1), SIK2, and SIK3 (IC50s = 6.56, 1.77, and 20.5 nM, respectively).1 It is selective for these SIKs over a panel of 468 additional kinases at 1 µM but does inhibit FRK, CSF1R, p38α, p38β, EphB1, and TNK2 (IC50s = 1.1, 9.66, 10.1, 9.64, 16.4, and 10.5 nM, respectively) and to a lesser extent KIT, Src, BRK, PDGFRβ, and NLK (IC50s = 153, 58.8, 24.1, 103, and 132 nM, respectively). YKL-06-061 (37.5 mM) induces pigmentation in human breast skin explants. In vivo, YKL-06-061 (20 mg/kg) decreases seizure severity in a mouse model of epilepsy induced by pentylenetetrazole (PTZ; Item No. 18682).2
WARNING This product is not for human or veterinary use.
1. A UV-
2. Blocking salt-